Member Log-in

I forgot my password

Not a Member? Register

Re-evaluating the Potential Impact and Cost-effectiveness of Rotavirus Vaccination in 73 Gavi Countries: A Modelling Study


Previous studies have found rotavirus vaccination to be highly cost-effective in low-income countries. However, updated evidence is now available for several inputs (ie, rotavirus disease mortality rates, rotavirus age distributions, vaccine timeliness, and vaccine efficacy by duration of follow-up), new rotavirus vaccines have entered the market, vaccine prices have decreased, and cost-effectiveness thresholds have been re-examined. We aimed to provide updated cost-effectiveness estimates to inform national decisions about the new introduction and current use of rotavirus vaccines in Gavi countries.


Over the period 2018–27, rotavirus vaccination has the potential to prevent nearly 600 000 deaths in Gavi countries. Averted outpatient visits and hospitalizations could lead to treatment savings of approximately $484·1 million from the government perspective and $878·0 million from the societal perspective. The discounted dollars per disability-adjusted life-year averted has a very high probability (>90%) of being less than 0·5 times the gross domestic product per capita in 54 countries, and less than 1·0 times gross domestic product per capita in 63 countries.


Rotavirus vaccination continues to represent good value for money across most Gavi countries despite lower rotavirus mortality estimates and more stringent willingness-to-pay thresholds.

You May Also Like

Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30

ABSTRACT Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization … Continued

LNCT Materials to Help you Make the Case for Investing in Immunization

Why We Need to Make a Case for Investment Maintaining a high performing immunization program requires sustained commitment and funding over time.  Ongoing communication and advocacy are needed to maintain investments and to stimulate additional investments to achieve health goals. Advocating for resources for immunization at national and sub-national levels requires demonstrating the health and … Continued

Teaching Vaccine Economics Everywhere (TVEE) Course Materials

1.     Health Economics for Vaccines The process of creating vaccines, manufacturing, distributing, and injecting them into individuals is a complex process requiring multiple decisions by multiple groups and individuals. On the supply side there are pharmaceutical companies, regulatory authorities, distributors, and thousands of health care workers who have to make strategic choices. On the demand side … Continued

Choose a Language